Simvastatin is associated with decreased risk of Parkinson disease

Annals of Neurology

Volumn 81, Issue 2, 2017, Pages 329-330

  Brakedal, Brage ^a,b   Haugarvoll, Kristoffer ^a,b   Tzoulis, Charalampos ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; METFORMIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DIABETES MELLITUS; DIABETIC PATIENT; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG USE; HUMAN; LETTER; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE DATABASE; RISK REDUCTION; SEX DIFFERENCE; ANIMAL; DISEASE MODEL;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PARKINSON DISEASE; SIMVASTATIN;

EID: 85013680546     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24857     Document Type: Letter

References (5)

1. Lin KD, Yang CY, Lee MY, et al. Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol 2016;80:532–540.
2. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Nor Epidemiol 2008;18:129–136.
3. Hernan MA, Logroscino G, Rodriguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004;251(suppl 7):vII14–vII17.
4. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–535.
5. Bai S, Song Y, Huang X, et al. Statin use and the risk of Parkinson's disease: an updated meta-analysis. PLoS One 2016;11:e0152564.